Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

By sjmartinez • December 20, 2023

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, Sun Q, Tan SY, Koeffler HP, Feng N, Chen YQ. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2023 Dec 20:e2304939. doi: 10.1002/advs.202304939. Epub ahead of print. PMID: 38115765.

Tags: castration-resistant prostate cancer, Cedars Sinai DoM, Drug-tolerant persister, Hematology/Oncology, peroxiredoxin 5, polaprezinc, Publications, stachyose

Related Posts

Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics Databases

Liang J, Rastegar R, El Helou M, Mathur K, Larson BK, Waters K, Vasireddy A, Randhawa N, Mubarak M, Advani R, Osipov A, Gong J,[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Effectiveness of mailed versus in-person PAP initiation in VA’s TeleSleep program

Gomez A, Sarmiento KF, Smith C, Mitchell M, Lee D, Totten A, Sanders E, Ryden AM, Seo J, Bhattacharyya S, Harris B, Mempin R, Moghtaderi[...]